Virax Biolabs Group (NASDAQ:VRAX) Stock Price Down 3.9% – What’s Next?

Virax Biolabs Group Limited (NASDAQ:VRAX) shares traded down 3.9% on Friday . The company traded as low as $1.20 and last traded at $1.22. 42,604 shares traded hands during mid-day trading, a decline of 98% from the average session volume of 2,058,643 shares. The stock had previously closed at $1.27.

Virax Biolabs Group Stock Down 3.9 %

The company’s fifty day moving average price is $1.74 and its two-hundred day moving average price is $2.01.

Hedge Funds Weigh In On Virax Biolabs Group

An institutional investor recently bought a new position in Virax Biolabs Group stock. XTX Topco Ltd acquired a new position in shares of Virax Biolabs Group Limited (NASDAQ:VRAX) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm acquired 11,863 shares of the company’s stock, valued at approximately $27,000. XTX Topco Ltd owned approximately 0.37% of Virax Biolabs Group as of its most recent filing with the Securities & Exchange Commission. 8.61% of the stock is owned by institutional investors and hedge funds.

Virax Biolabs Group Company Profile

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name.